Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The neuronal acetylcholine receptor alpha-3 beta-4 is a heteropentameric, ligand-gated ion channel found primarily in autonomic ganglia and certain brain regions[4][5]. Composed of alpha-3 (CHRNA3) and beta-4 (CHRNB4) subunits, it enables rapid neurotransmission by opening a cation-permeable channel upon binding acetylcholine or other agonists[1][2][5]. Activation of this receptor leads to sodium and potassium influx, membrane depolarization, and initiation of neuronal excitation, playing a key role in autonomic nervous system communication and some aspects of addiction neurobiology[4][5]. It is studied as a drug target for modulating addiction and autonomic dysfunction; multiple endogenous and exogenous agonists and antagonists are known to interact with the α3β4 nAChR[4][5].
Agonist (direct channel opening, e.g., acetylcholine, nicotine); Partial agonist (partial channel opening, e.g., cytisine); Competitive antagonist (blockade of the acetylcholine binding site, e.g., DHβE, SR 16584); Noncompetitive antagonist (allosteric inhibition, e.g., bupropion, mecamylamine, dextromethorphan)
20 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neuronal acetylcholine receptor alpha-3 beta-4 (α3β4 nAChR).